NCT01168934 - A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Healthy

Interventions

DRUG

crizotinib

Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.

DRUG

crizotinib

Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels